

Barbara Picconi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/488106/publications.pdf>

Version: 2024-02-01

138
papers

11,811
citations

24978

57
h-index

28224

105
g-index

139
all docs

139
docs citations

139
times ranked

11512
citing authors

#	ARTICLE	IF	CITATIONS
1	Basic mechanisms of plasticity and learning. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2022, 184, 21-34.	1.0	9
2	Long-Term Shaping of Corticostriatal Synaptic Activity by Acute Fasting. International Journal of Molecular Sciences, 2021, 22, 1916.	1.8	2
3	Progress of clinical neuroscience in movement disorders: Technical and methodological developments. Journal of Neuroscience Methods, 2021, 349, 109034.	1.3	0
4	Alpha-Synuclein as a Prominent Actor in the Inflammatory Synaptopathy of Parkinson's Disease. International Journal of Molecular Sciences, 2021, 22, 6517.	1.8	38
5	Dopamine-dependent early synaptic and motor dysfunctions induced by α -synuclein in the nigrostriatal circuit. Brain, 2021, 144, 3477-3491.	3.7	49
6	Transcranial Magnetic Stimulation Exerts "Rejuvenation" Effects on Corticostriatal Synapses after Partial Dopamine Depletion. Movement Disorders, 2021, 36, 2254-2263.	2.2	10
7	Serotonin drives striatal synaptic plasticity in a sex-related manner. Neurobiology of Disease, 2021, 158, 105448.	2.1	3
8	CalDAG-GEFI mediates striatal cholinergic modulation of dendritic excitability, synaptic plasticity and psychomotor behaviors. Neurobiology of Disease, 2021, 158, 105473.	2.1	8
9	Effects of uremic toxins on hippocampal synaptic transmission: implication for neurodegeneration in chronic kidney disease. Cell Death Discovery, 2021, 7, 295.	2.0	8
10	Rapamycin, by Inhibiting mTORC1 Signaling, Prevents the Loss of Striatal Bidirectional Synaptic Plasticity in a Rat Model of L-DOPA-Induced Dyskinesia. Frontiers in Aging Neuroscience, 2020, 12, 230.	1.7	18
11	Maternal stress programs accelerated aging of the basal ganglia motor system in offspring. Neurobiology of Stress, 2020, 13, 100265.	1.9	3
12	Effects of safinamide on the glutamatergic striatal network in experimental Parkinson's disease. Neuropharmacology, 2020, 170, 108024.	2.0	8
13	From cell lines to pluripotent stem cells for modelling Parkinson's Disease. Journal of Neuroscience Methods, 2020, 340, 108741.	1.3	26
14	Corticostriatal synaptic plasticity alterations in the R6/1 transgenic mouse model of Huntington's disease. Journal of Neuroscience Research, 2019, 97, 1655-1664.	1.3	10
15	Blunting neuroinflammation with resolvin D1 prevents early pathology in a rat model of Parkinson's disease. Nature Communications, 2019, 10, 3945.	5.8	127
16	Dopamine drives binge-like consumption of a palatable food in experimental Parkinsonism. Movement Disorders, 2019, 34, 821-831.	2.2	11
17	Quantal Release of Dopamine and Action Potential Firing Detected in Midbrain Neurons by Multifunctional Diamond-Based Microarrays. Frontiers in Neuroscience, 2019, 13, 288.	1.4	34
18	Alpha-synuclein targets GluN2A NMDA receptor subunit causing striatal synaptic dysfunction and visuospatial memory alteration. Brain, 2019, 142, 1365-1385.	3.7	82

#	ARTICLE	IF	CITATIONS
19	Differential effect of FHM2 mutation on synaptic plasticity in distinct hippocampal regions. <i>Cephalalgia</i> , 2019, 39, 1333-1338.	1.8	8
20	Striatal spreading depolarization: Possible implication in levodopa-induced dyskinesia-like behavior. <i>Movement Disorders</i> , 2019, 34, 832-844.	2.2	6
21	NMDA receptor GluN2D subunit participates to levodopa-induced dyskinesia pathophysiology. <i>Neurobiology of Disease</i> , 2019, 121, 338-349.	2.1	24
22	Synaptic plasticity and levodopa-induced dyskinesia: electrophysiological and structural abnormalities. <i>Journal of Neural Transmission</i> , 2018, 125, 1263-1271.	1.4	39
23	Motor learning and metaplasticity in striatal neurons: relevance for Parkinson's disease. <i>Brain</i> , 2018, 141, 505-520.	3.7	62
24	Motor complications in Parkinson's disease: Striatal molecular and electrophysiological mechanisms of dyskinesias. <i>Movement Disorders</i> , 2018, 33, 867-876.	2.2	82
25	Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts. <i>Annals of Neurology</i> , 2018, 84, 797-811.	2.8	225
26	Intermittent theta-burst stimulation rescues dopamine-dependent corticostriatal synaptic plasticity and motor behavior in experimental parkinsonism: Possible role of glial activity. <i>Movement Disorders</i> , 2017, 32, 1035-1046.	2.2	38
27	Switching on the lights of dyskinesia: Perspectives and limits of the optogenetic approaches. <i>Movement Disorders</i> , 2017, 32, 485-486.	2.2	5
28	Rabphilin 3A: A novel target for the treatment of levodopa-induced dyskinesias. <i>Neurobiology of Disease</i> , 2017, 108, 54-64.	2.1	40
29	Early synaptic dysfunction in Parkinson's disease: Insights from animal models. <i>Movement Disorders</i> , 2016, 31, 802-813.	2.2	127
30	Hyperkinetic disorders and loss of synaptic downscaling. <i>Nature Neuroscience</i> , 2016, 19, 868-875.	7.1	98
31	Memantine alters striatal plasticity inducing a shift of synaptic responses toward long-term depression. <i>Neuropharmacology</i> , 2016, 101, 341-350.	2.0	16
32	Alpha-Synuclein Produces Early Behavioral Alterations via Striatal Cholinergic Synaptic Dysfunction by Interacting With GluN2D N-Methyl-D-Aspartate Receptor Subunit. <i>Biological Psychiatry</i> , 2016, 79, 402-414.	0.7	77
33	Modulation of serotonergic transmission by eltoprazine in L-DOPA-induced dyskinesia: Behavioral, molecular, and synaptic mechanisms. <i>Neurobiology of Disease</i> , 2016, 86, 140-153.	2.1	53
34	Interaction between basal ganglia and limbic circuits in learning and memory processes. <i>Parkinsonism and Related Disorders</i> , 2016, 22, S65-S68.	1.1	18
35	Rhes influences striatal cAMP/PKA-dependent signaling and synaptic plasticity in a gender-sensitive fashion. <i>Scientific Reports</i> , 2015, 5, 10933.	1.6	38
36	NMDA receptor GluN2A/GluN2B subunit ratio as synaptic trait of levodopa-induced dyskinesias: from experimental models to patients. <i>Frontiers in Cellular Neuroscience</i> , 2015, 9, 245.	1.8	68

#	ARTICLE	IF	CITATIONS
37	Levodopa-induced plasticity: a double-edged sword in Parkinson's disease?. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2015, 370, 20140184.	1.8	71
38	Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease. <i>Progress in Neurobiology</i> , 2015, 132, 96-168.	2.8	379
39	Derangement of Ras-Guanine Nucleotide-Releasing Factor 1 (Ras-GRF1) and Extracellular Signal-Regulated Kinase (ERK) Dependent Striatal Plasticity in L-DOPA-Induced Dyskinesia. <i>Biological Psychiatry</i> , 2015, 77, 106-115.	0.7	67
40	L-DOPA reverses the impairment of Dentate Gyrus LTD in experimental parkinsonism via β -adrenergic receptors. <i>Experimental Neurology</i> , 2014, 261, 377-385.	2.0	9
41	Targeting metabotropic glutamate receptors as a new strategy against levodopa-induced dyskinesia in Parkinson's disease?. <i>Movement Disorders</i> , 2014, 29, 715-719.	2.2	14
42	Direct and indirect pathways of basal ganglia: a critical reappraisal. <i>Nature Neuroscience</i> , 2014, 17, 1022-1030.	7.1	598
43	Environmental enrichment restores CA1 hippocampal LTP and reduces severity of seizures in epileptic mice. <i>Experimental Neurology</i> , 2014, 261, 320-327.	2.0	25
44	Glutamate Receptors and Levodopa-Induced Dyskinesia. , 2014, , 229-243.		2
45	New experimental and clinical links between the hippocampus and the dopaminergic system in Parkinson's disease. <i>Lancet Neurology</i> , The, 2013, 12, 811-821.	4.9	165
46	Region-specific restoration of striatal synaptic plasticity by dopamine grafts in experimental parkinsonism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E4375-84.	3.3	26
47	Ischemic-LTP in Striatal Spiny Neurons of both Direct and Indirect Pathway Requires the Activation of D1-Like Receptors and NO/Soluble Guanylate Cyclase/cGMP Transmission. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 278-286.	2.4	13
48	BDNF-TrkB signaling in striatopallidal neurons controls inhibition of locomotor behavior. <i>Nature Communications</i> , 2013, 4, 2031.	5.8	40
49	New synaptic and molecular targets for neuroprotection in Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 51-60.	2.2	34
50	Rebalance of Striatal NMDA/AMPA Receptor Ratio Underlies the Reduced Emergence of Dyskinesia During D2-Like Dopamine Agonist Treatment in Experimental Parkinson's Disease. <i>Journal of Neuroscience</i> , 2012, 32, 17921-17931.	1.7	67
51	Critical role of calcitonin gene-related peptide receptors in cortical spreading depression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 18985-18990.	3.3	113
52	N-Methyl-d-aspartate (NMDA) Receptor Composition Modulates Dendritic Spine Morphology in Striatal Medium Spiny Neurons. <i>Journal of Biological Chemistry</i> , 2012, 287, 18103-18114.	1.6	38
53	Mechanisms underlying altered striatal synaptic plasticity in old A53T α -synuclein overexpressing mice. <i>Neurobiology of Aging</i> , 2012, 33, 1792-1799.	1.5	37
54	Targeting NR2A-containing NMDA receptors reduces L-DOPA-induced dyskinesias. <i>Neurobiology of Aging</i> , 2012, 33, 2138-2144.	1.5	60

#	ARTICLE	IF	CITATIONS
55	Functional interactions within striatal microcircuit in animal models of Huntington's disease. <i>Neuroscience</i> , 2012, 211, 165-184.	1.1	17
56	A2A Adenosine Receptor Antagonism Enhances Synaptic and Motor Effects of Cocaine via CB1 Cannabinoid Receptor Activation. <i>PLoS ONE</i> , 2012, 7, e38312.	1.1	18
57	Corticostriatal Plastic Changes in Experimental L-DOPA-Induced Dyskinesia. <i>Parkinson's Disease</i> , 2012, 2012, 1-10.	0.6	15
58	Rhes-mTORC1 interaction: A new possible therapeutic target in Parkinson's disease and L-dopa-induced dyskinesia?. <i>Movement Disorders</i> , 2012, 27, 815-815.	2.2	3
59	Synaptic Dysfunction in Parkinson's Disease. <i>Advances in Experimental Medicine and Biology</i> , 2012, 970, 553-572.	0.8	209
60	Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease. <i>Brain</i> , 2012, 135, 1884-1899.	3.7	124
61	Prenatal stress and hippocampal BDNF expression: a fading imperative. <i>Journal of Physiology</i> , 2012, 590, 1309-1310.	1.3	4
62	Theta-burst stimulation and striatal plasticity in experimental parkinsonism. <i>Experimental Neurology</i> , 2012, 236, 395-398.	2.0	23
63	Striatum-hippocampus balance: From physiological behavior to interneuronal pathology. <i>Progress in Neurobiology</i> , 2011, 94, 102-114.	2.8	43
64	Higher free d-aspartate and N-methyl-d-aspartate levels prevent striatal depotentiation and anticipate L-DOPA-induced dyskinesia. <i>Experimental Neurology</i> , 2011, 232, 240-250.	2.0	39
65	Dopamine-Dependent Long-Term Depression Is Expressed in Striatal Spiny Neurons of Both Direct and Indirect Pathways: Implications for Parkinson's Disease. <i>Journal of Neuroscience</i> , 2011, 31, 12513-12522.	1.7	94
66	Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia. <i>Brain</i> , 2011, 134, 375-387.	3.7	125
67	The Distinct Role of Medium Spiny Neurons and Cholinergic Interneurons in the D ₂ /A _{2A} Receptor Interaction in the Striatum: Implications for Parkinson's Disease. <i>Journal of Neuroscience</i> , 2011, 31, 1850-1862.	1.7	140
68	Mitochondria and the Link Between Neuroinflammation and Neurodegeneration. <i>Journal of Alzheimer's Disease</i> , 2010, 20, S369-S379.	1.2	118
69	Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to bedside gap. <i>Lancet Neurology</i> , The, 2010, 9, 1106-1117.	4.9	329
70	L-DOPA-induced sprouting of serotonin axon terminals: A useful biomarker for dyskinesias?. <i>Annals of Neurology</i> , 2010, 68, 578-580.	2.8	10
71	Direct and indirect pathways in levodopa-induced dyskinesia: A more complex matter than a network imbalance. <i>Movement Disorders</i> , 2010, 25, 1527-1529.	2.2	5
72	Synaptic dysfunction in Parkinson's disease. <i>Biochemical Society Transactions</i> , 2010, 38, 493-497.	1.6	96

#	ARTICLE	IF	CITATIONS
73	Distinct Levels of Dopamine Denervation Differentially Alter Striatal Synaptic Plasticity and NMDA Receptor Subunit Composition. <i>Journal of Neuroscience</i> , 2010, 30, 14182-14193.	1.7	155
74	TrkB/BDNF-Dependent Striatal Plasticity and Behavior in a Genetic Model of Epilepsy: Modulation by Valproic Acid. <i>Neuropsychopharmacology</i> , 2010, 35, 1531-1540.	2.8	32
75	Impaired Plasticity at Specific Subset of Striatal Synapses in the Ts65Dn Mouse Model of Down Syndrome. <i>Biological Psychiatry</i> , 2010, 67, 666-671.	0.7	28
76	Hippocampal Synaptic Plasticity, Memory, and Epilepsy: Effects of Long-Term Valproic Acid Treatment. <i>Biological Psychiatry</i> , 2010, 67, 567-574.	0.7	68
77	Downstream mechanisms triggered by mitochondrial dysfunction in the basal ganglia: From experimental models to neurodegenerative diseases. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2010, 1802, 151-161.	1.8	31
78	Electrophysiological actions of zonisamide on striatal neurons: Selective neuroprotection against complex I mitochondrial dysfunction. <i>Experimental Neurology</i> , 2010, 221, 217-224.	2.0	28
79	mTOR inhibitor rapamycin suppresses striatal post-ischemic LTP. <i>Experimental Neurology</i> , 2010, 226, 328-331.	2.0	23
80	Decreased NR2B Subunit Synaptic Levels Cause Impaired Long-Term Potentiation But Not Long-Term Depression. <i>Journal of Neuroscience</i> , 2009, 29, 669-677.	1.7	126
81	Epilepsy-induced abnormal striatal plasticity in Bassoon mutant mice. <i>European Journal of Neuroscience</i> , 2009, 29, 1979-1993.	1.2	26
82	A2A adenosine receptor antagonists protect the striatum against rotenone-induced neurotoxicity. <i>Experimental Neurology</i> , 2009, 217, 231-234.	2.0	19
83	Short-term and long-term plasticity at corticostriatal synapses: Implications for learning and memory. <i>Behavioural Brain Research</i> , 2009, 199, 108-118.	1.2	115
84	Molecular mechanisms underlying levodopa-induced dyskinesia. <i>Movement Disorders</i> , 2008, 23, S570-S579.	2.2	99
85	L-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation. <i>Neurobiology of Disease</i> , 2008, 29, 327-335.	2.1	105
86	Plasticity and repair in the post-ischemic brain. <i>Neuropharmacology</i> , 2008, 55, 353-362.	2.0	132
87	Acetyl-L-Carnitine selectively prevents post-ischemic LTP via a possible action on mitochondrial energy metabolism. <i>Neuropharmacology</i> , 2008, 55, 223-229.	2.0	25
88	Striatal synaptic changes in experimental parkinsonism: Role of NMDA receptor trafficking in PSD. <i>Parkinsonism and Related Disorders</i> , 2008, 14, S145-S149.	1.1	14
89	Neuroinflammation and synaptic plasticity: theoretical basis for a novel, immune-centred, therapeutic approach to neurological disorders. <i>Trends in Pharmacological Sciences</i> , 2008, 29, 402-412.	4.0	172
90	The Endocannabinoid System in Parkinsons Disease. <i>Current Pharmaceutical Design</i> , 2008, 14, 2337-2346.	0.9	52

#	ARTICLE	IF	CITATIONS
91	Electrophysiology and Pharmacology of Striatal Neuronal Dysfunction Induced by Mitochondrial Complex I Inhibition. <i>Journal of Neuroscience</i> , 2008, 28, 8040-8052.	1.7	54
92	Na + /Ca 2+ Exchanger Maintains Ionic Homeostasis in the Peri-Infarct Area. <i>Stroke</i> , 2007, 38, 1614-1620.	1.0	11
93	Dopamine-mediated regulation of corticostriatal synaptic plasticity. <i>Trends in Neurosciences</i> , 2007, 30, 211-219.	4.2	707
94	Interaction of A2A adenosine and D2 dopamine receptors modulates corticostriatal glutamatergic transmission. <i>Neuropharmacology</i> , 2007, 53, 783-789.	2.0	53
95	Memantine reduces neuronal dysfunctions triggered by in vitro ischemia and 3-nitropropionic acid. <i>Experimental Neurology</i> , 2007, 207, 218-226.	2.0	32
96	Plastic abnormalities in experimental Huntington's disease. <i>Current Opinion in Pharmacology</i> , 2007, 7, 106-111.	1.7	30
97	Neuronal networks and synaptic plasticity in Parkinson's disease: beyond motor deficits. <i>Parkinsonism and Related Disorders</i> , 2007, 13, S259-S262.	1.1	55
98	Synaptic plasticity during recovery from permanent occlusion of the middle cerebral artery. <i>Neurobiology of Disease</i> , 2007, 27, 44-53.	2.1	63
99	Mapping P2X and P2Y receptor proteins in striatum and substantia nigra: An immunohistological study. <i>Purinergic Signalling</i> , 2007, 3, 389-398.	1.1	69
100	Striatal metabotropic glutamate receptors as a target for pharmacotherapy in Parkinson's disease. <i>Amino Acids</i> , 2007, 32, 189-195.	1.2	39
101	NR2B-containing NMDA receptors promote the neurotoxic effects of 3-nitropropionic acid but not of rotenone in the striatum. <i>Experimental Neurology</i> , 2006, 202, 470-479.	2.0	27
102	L-DOPA treatment of parkinsonian rats changes the expression of Src, Lyn and PKC kinases. <i>Neuroscience Letters</i> , 2006, 398, 211-214.	1.0	18
103	Deficits of glutamate transmission in the striatum of toxic and genetic models of Huntington's disease. <i>Neuroscience Letters</i> , 2006, 410, 6-10.	1.0	15
104	Acetyl-L-carnitine protects striatal neurons against in vitro ischemia: The role of endogenous acetylcholine. <i>Neuropharmacology</i> , 2006, 50, 917-923.	2.0	27
105	Deficits of glutamate transmission in the striatum of experimental hemiballism. <i>Neuroscience</i> , 2006, 143, 213-221.	1.1	7
106	NR2B Subunit Exerts a Critical Role in Postischemic Synaptic Plasticity. <i>Stroke</i> , 2006, 37, 1895-1901.	1.0	63
107	Pathways of neurodegeneration and experimental models of basal ganglia disorders: Downstream effects of mitochondrial inhibition. <i>European Journal of Pharmacology</i> , 2006, 545, 65-72.	1.7	22
108	A convergent model for cognitive dysfunctions in Parkinson's disease: the critical dopamine/acetylcholine synaptic balance. <i>Lancet Neurology</i> , The, 2006, 5, 974-983.	4.9	289

#	ARTICLE	IF	CITATIONS
109	Plastic and behavioral abnormalities in experimental Huntington's disease: A crucial role for cholinergic interneurons. <i>Neurobiology of Disease</i> , 2006, 22, 143-152.	2.1	79
110	Multiple Mechanisms Underlying the Neuroprotective Effects of Antiepileptic Drugs Against In Vitro Ischemia. <i>Stroke</i> , 2006, 37, 1319-1326.	1.0	95
111	A Critical Interaction between NR2B and MAGUK in L-DOPA Induced Dyskinesia. <i>Journal of Neuroscience</i> , 2006, 26, 2914-2922.	1.7	243
112	Pathological Synaptic Plasticity in the Striatum: Implications for Parkinson's Disease. <i>NeuroToxicology</i> , 2005, 26, 779-783.	1.4	80
113	Subthalamic nucleus lesion reverses motor abnormalities and striatal glutamatergic overactivity in experimental parkinsonism. <i>Neuroscience</i> , 2005, 133, 831-840.	1.1	54
114	Chronic Haloperidol Promotes Corticostriatal Long-Term Potentiation by Targeting Dopamine D2L Receptors. <i>Journal of Neuroscience</i> , 2004, 24, 8214-8222.	1.7	90
115	Therapeutic doses of L-dopa reverse hypersensitivity of corticostriatal D2-dopamine receptors and glutamatergic overactivity in experimental parkinsonism. <i>Brain</i> , 2004, 127, 1661-1669.	3.7	78
116	Abnormal Ca ²⁺ -Calmodulin-Dependent Protein Kinase II Function Mediates Synaptic and Motor Deficits in Experimental Parkinsonism. <i>Journal of Neuroscience</i> , 2004, 24, 5283-5291.	1.7	136
117	A model of l-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. <i>Neurobiology of Disease</i> , 2004, 16, 110-123.	2.1	282
118	Neuronal vulnerability following inhibition of mitochondrial complex II: a possible ionic mechanism for Huntington's disease. <i>Molecular and Cellular Neurosciences</i> , 2004, 25, 9-20.	1.0	47
119	Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism. <i>Journal of Neurochemistry</i> , 2003, 85, 1018-1025.	2.1	145
120	Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. <i>Nature Neuroscience</i> , 2003, 6, 501-506.	7.1	791
121	Lamotrigine and remacemide protect striatal neurons against in vitro ischemia: an electrophysiological study. <i>Experimental Neurology</i> , 2003, 182, 461-469.	2.0	18
122	Striatal metabotropic glutamate receptor function following experimental parkinsonism and chronic levodopa treatment. <i>Brain</i> , 2002, 125, 2635-2645.	3.7	76
123	Experimental Parkinsonism Modulates Multiple Genes Involved in the Transduction of Dopaminergic Signals in the Striatum. <i>Neurobiology of Disease</i> , 2002, 10, 387-395.	2.1	43
124	Experimental Parkinsonism Alters Endocannabinoid Degradation: Implications for Striatal Glutamatergic Transmission. <i>Journal of Neuroscience</i> , 2002, 22, 6900-6907.	1.7	303
125	Cocaine and Amphetamine Depress Striatal GABAergic Synaptic Transmission through D2 Dopamine Receptors. <i>Neuropsychopharmacology</i> , 2002, 26, 164-175.	2.8	78
126	Tissue plasminogen activator is required for corticostriatal long-term potentiation. <i>European Journal of Neuroscience</i> , 2002, 16, 713-721.	1.2	52

#	ARTICLE	IF	CITATIONS
127	A Synaptic Mechanism Underlying the Behavioral Abnormalities Induced by Manganese Intoxication. <i>Neurobiology of Disease</i> , 2001, 8, 419-432.	2.1	72
128	Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons. <i>Neuroscience</i> , 2001, 106, 579-587.	1.1	292
129	Role of tonically-active neurons in the control of striatal function: Cellular mechanisms and behavioral correlates. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2001, 25, 211-230.	2.5	54
130	Ionic mechanisms underlying differential vulnerability to ischemia in striatal neurons. <i>Progress in Neurobiology</i> , 2001, 63, 687-696.	2.8	59
131	Inhibition of Mitochondrial Complex II Induces a Long-Term Potentiation of NMDA-Mediated Synaptic Excitation in the Striatum Requiring Endogenous Dopamine. <i>Journal of Neuroscience</i> , 2001, 21, 5110-5120.	1.7	152
132	An abnormal striatal synaptic plasticity may account for the selective neuronal vulnerability in Huntington's disease. <i>Neurological Sciences</i> , 2001, 22, 61-62.	0.9	14
133	Dopaminergic control of synaptic plasticity in the dorsal striatum. <i>European Journal of Neuroscience</i> , 2001, 13, 1071-1077.	1.2	319
134	Dopamine denervation induces neurotensin immunoreactivity in GABA-parvalbumin striatal neurons. <i>Synapse</i> , 2001, 41, 360-362.	0.6	5
135	Dopamine and cAMP-Regulated Phosphoprotein 32 kDa Controls Both Striatal Long-Term Depression and Long-Term Potentiation, Opposing Forms of Synaptic Plasticity. <i>Journal of Neuroscience</i> , 2000, 20, 8443-8451.	1.7	337
136	Is Pharmacological Neuroprotection Dependent on Reduced Glutamate Release?. <i>Stroke</i> , 2000, 31, 766-773.	1.0	71
137	Unilateral Dopamine Denervation Blocks Corticostriatal LTP. <i>Journal of Neurophysiology</i> , 1999, 82, 3575-3579.	0.9	214
138	Protein phosphatase inhibitors induce modification of synapse structure and tau hyperphosphorylation in cultured rat hippocampal neurons. , 1997, 48, 425-438.		48